Bank Of New York Mellon Corp Travere Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $3.94 Million - $5.57 Million	213,223 New	213,223 $4.48 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $541,065 - $676,154	23,617 Added 12.4%	214,118 $5.28 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $634,188 - $908,882	-30,286 Reduced 13.72%	190,501 $4.62 Million
Q1 2022 May 11, 2022	SELL	$23.61 - $30.6 $30,716 - $39,810	-1,301 Reduced 0.59%	220,787 $5.69 Million
Q4 2021 Feb 11, 2022	SELL	$24.34 - $31.17 $28,283 - $36,219	-1,162 Reduced 0.52%	222,088 $6.89 Million
Q3 2021 Nov 12, 2021	BUY	$12.98 - $25.03 $256,952 - $495,493	19,796 Added 9.73%	223,250 $5.41 Million
Q2 2021 Aug 11, 2021	SELL	$14.11 - $26.4 $41,737 - $78,091	-2,958 Reduced 1.43%	203,454 $2.97 Million
Q1 2021 May 13, 2021	BUY	$23.37 - $31.77 $250,596 - $340,669	10,723 Added 5.48%	206,412 $5.15 Million
Q4 2020 Feb 09, 2021	BUY	$19.17 - $27.87 $3.75 Million - $5.45 Million	195,689 New	195,689 $5.33 Million

214

94.3M

1.2M

778K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.32B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.